Alternate-Day Buprenorphine Administration. Phase VI - 7

This study has been completed.
Sponsor:
Collaborator:
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000225
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: June 2004
  Purpose
The purpose of this study is to determine if four times a subject's daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects.

Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Alternate-Day Buprenorphine Administration. Phase VI

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Opioid withdrawal
  • Opioid agonist effects
  • Dose identification
  • Pupil diameter

Estimated Enrollment: 0
Study Start Date: December 1992
  Eligibility

Ages Eligible for Study:   21 Years to 51 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000225

Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Vermont
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

Publications:
patry, Bickel, Tzanis, Badger (in preparation). Every fourth day dosing with buprenorphine (1) A comparison of four schedules under blind-dosing procedures.. Patry, Bickel, Tzanis, Badger (in preparation). Every fourth day dosing with buprenorphine (1) A comparison of four different dosing schedules under blind-dosing procedures.

ClinicalTrials.gov Identifier: NCT00000225     History of Changes
Other Study ID Numbers: NIDA-06969-7  R01-06969-7 
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists

ClinicalTrials.gov processed this record on August 25, 2016